Why CODE matters
There is an enormous effort driving innovation in anti-cancer medicines, yet surprisingly little is known about how different drugs are being used in clinical practice today.
The Collaboration for Oncology Data in Europe (CODE) aims to expand our knowledge of anti-cancer medicines use by supporting the development of a dedicated Oncology Data Network. The data collated will enable the oncology community to derive greater value from anti-cancer medicines for patients.
Learn moreWhat CODE does
The Collaboration for Oncology Data in Europe (CODE) is supporting the creation of a large-scale Oncology Data Network that will collate comprehensive, up-to-date data to describe how anti-cancer medicines are actually used in clinical practice. The technology platform has been designed to be able to aggregate data on anti-cancer medicine usage for all forms of cancer, in all patients and for all treatment centres across Europe who wish to join.
The aim is to collaborate with 200 cancer treatment centres in seven European countries in the first three years, scaling potentially to an estimated 2,000 treatment centres across Europe over 10 years.
For the first time, treatment centres joining the Oncology Data Network will be able to explore near real-time, clinically robust, real-world information that will describe how anti-cancer medicines are being used in today’s clinical practice, for which patients groups, and in which combinations and sequences, across Europe.
The members of CODE believe that creating this Oncology Data Network will pave the way for the European oncology community to increase its understanding of today’s clinical practice. Only by understanding how anti-cancer medicines are used will we create the necessary foundation for new approaches to access of innovative therapies, helping to connect treatment innovation to patient benefit and broaden the opportunity for individual patients to receive the therapies that are appropriate for them.
How it works
The Collaboration
The challenges of cancer data, and the nature of clinical practice in oncology, are so complex that a collaborative approach is vital. That’s why CODE has been established: to focus on an issue that touches multiple different stakeholders by facilitating contributions from healthcare professionals, professional societies, national agencies, governments and patient groups. This is how CODE will remain relevant and meet the needs of patients, physicians, treatment centres and the whole oncology community.
